With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...

Jonathan Van Ness is getting candid about his weight loss journey. In a vulnerable new video posted to TikTok this week, the ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

In this podcast, Motley Fool analyst Asit Sharma and host Ricky Mulvey check in on the year in investing. They discuss: What most of the biggest winners in the S&P 500 had in common. Why more ...

LA GLP1-RAs have shown at least equal reduction ... of these antibodies result in significant decrease in efficacy of the medication class. LA GLP1-RAs in studies to date appear to be a cost ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.